Guggenheim raises Pyxis Oncology stock price target to $7 on expanded trial data
PositiveFinancial Markets

Guggenheim has raised its price target for Pyxis Oncology's stock to $7 following promising data from an expanded clinical trial. This adjustment reflects growing confidence in the company's potential and could attract more investors, signaling a positive outlook for Pyxis as it continues to develop its oncology treatments.
— Curated by the World Pulse Now AI Editorial System







